Ipilimumab Boosts Survival, But With Adverse Events That Need Strict Oversight
This article was originally published in The Pink Sheet Daily
Phase III results highlight need for management of immune-related side effects with vigilant monitoring and early steroid treatment.
You may also be interested in...
Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.